CLDI vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

CLDI

57.4
AI Score
VS
CLDI Wins

MRNA

38.7
AI Score

Investment Advisor Scores

CLDI

57score
Recommendation
HOLD

MRNA

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLDI MRNA Winner
Revenue 45,000 1.94B MRNA
Net Income -25.43M -2.82B CLDI
Net Margin -56504.4% -145.2% MRNA
Operating Income -23.13M -3.07B CLDI
ROE 50.4% -32.6% CLDI
ROA -979.1% -22.9% MRNA
Total Assets 2.60M 12.34B MRNA
Cash 372,000 2.60B MRNA
Current Ratio 0.02 3.29 MRNA

Relative Price Performance (Last 90 Days)

CLDI 1M: -25.0% · 3M: -58.8% MRNA 1M: +2.2% · 3M: +265.4%

Current Technical Phase

CLDI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -23.6%), weak momentum, RSI 34

RSI (14): 34.5 · Price: $0.66

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53

RSI (14): 52.5 · Price: $231.35

Fundamentals Snapshot

Metric CLDI MRNA
Market Cap — —
Forward P/E -0.1 -53.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.3%
Gross Margin — -0.4%
Operating Margin 0.0% -0.8%
EPS -36.47 -6.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLDI is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.